Lilly strikes up to $5.9B cancer deal with Stipple Bio
Eli Lilly continues to be pharma’s biggest shopaholic. Lilly has enlisted Cambridge, MA-based startup Stipple Bio for a multibillion-dollar deal to develop new cancer treatments, marking what appears to be the Indianapolis drug giant’s second-largest ...
Stipple Bio CEO Jeff Landau at this year's Endpoints 11 awards (Adam Parshall for Endpoints News) November 16, 2026 04:01 PM EST Deals Lilly strikes up to $5.9B cancer deal with Stipple Bio Lei Lei Wu News Reporter Eli Lilly continues to be pharma’s biggest shopaholic. Lilly has enlisted Cambridge, MA-based startup Stipple Bio for a multibillion-dollar deal to develop new cancer treatments … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that